Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 18/20 | 0.67 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.60 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.60 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.60 |
| ▸ | CDK2 | P24941 | 2/20 | 0.60 |
| ▸ | CDK9 | P50750 | 2/20 | 0.60 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.60 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.60 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.60 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.60 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20485693 | 0.87 | FYN (0.65) | FYN | |
| SCHEMBL16332597 | 0.83 | FYN (0.66) | FYNDYRK3CCNT1CCNA2CDK2 | |
| SCHEMBL2949541 | 0.80 | FYN (0.69) | FYNDYRK3CCNT1CCNA2CDK2 | |
| SCHEMBL18613503 | 0.80 | FYN (1.00) | FYN | |
| SCHEMBL14373185 | 0.78 | FYN (0.78) | FYNDYRK3CCNT1CCNA2CDK2 | |
| SCHEMBL16331230 | 0.78 | FYN (1.00) | FYN | |
| SCHEMBL13234218 | 0.77 | FYN (0.77) | FYNDYRK3CCNT1CCNA2CDK2 | |
| SCHEMBL1055826 | 0.76 | FYN (0.79) | FYNDYRK3CCNT1CCNA2CDK2 | |
| SCHEMBL18613352 | 0.76 | FYN (1.00) | FYN | |
| SCHEMBL18613397 | 0.76 | FYN (1.00) | FYNDYRK3CCNT1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021513-A1 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | BIOGEN IDEC MA INC. (US) | 2011-01-27 | — | — | US | claimed |
| US-20110021513-A1 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | BIOGEN IDEC MA INC. (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021513-A1 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | IRAK1, IRAK2, IRAK3 | FYN 666/4885DYRK3 2299/4885CCNT1 4289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.